Intellectual Property,
Corporate
Jun. 29, 2017
Proposed generic drugs legislation divides stakeholders
The CREATES Act of 2017 is proposed bipartisan legislation targeting actions by brand name drug manufacturers that can delay entry by generic drug manufacturers.
William Diaz
McDermot Will & Emery LLP
4 Park Plz Ste 1700
Irvine , CA 92614
Phone: (949) 757-7129
Fax: (949) 851-9348
Email: wdiaz@mwe.com
Georgetown Univ Law Center
Michelle Lowery
McDermott, Will & Emery LLP
2049 Century Park E Ste 3800
Los Angeles , CA 90067
Phone: (310) 551-9309
Fax: (310) 317-7213
Email: mslowery@mwe.com
Loyola Law School
Michelle is a partner in the firm's antitrust group. She specializes in complex antitrust litigation ranging from class action conspiracy cases to contracting and competitor cases.
Lauren Salins
McDermott Will & EmeryEmail: lsalins@mwe.com
Loyola University of Chicago School of Law
The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2017 is proposed bipartisan legislation targeting actions by brand name drug manufacturers that can delay entry by generic drug manufacturers. In June 2016, Sens. Patrick Leahy (D-Vt.), Chuck Grassley (R-Iowa), Amy Klobuchar (D-Minn.) and Mike Lee (R-Utah) of the Senate Judiciary Committee introduced the CREATES Act of 2016 to the Senate. After lying dormant for several months, the 2017 act...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In